STOCKHOLDERS' DEFICIT |
6 Months Ended |
|---|---|
Jun. 30, 2022 | |
| STOCKHOLDERS' DEFICIT | |
| STOCKHOLDERS' DEFICIT |
NOTE 7: STOCKHOLDERS’ DEFICIT During the six months ended June 30, 2022, $1,432,979 in outstanding principal of convertible notes were converted into 2,482,698 shares of common stock. Underwriting Agreement and Public Offering On May 5, 2022, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Alexander Capital, L.P., acting as representative (the “Representative”) of the several underwriters named in the Underwriting Agreement (the “Underwriters”), relating to the Company’s underwritten the offering (the “Offering”) pursuant to which the Company agreed to issue and sell 37,389,800 shares (the “Firm Shares”) of the Company’s common stock. The Firm Shares were sold to the public at a combined public offering price of $0.25 per share and were purchased by the Underwriters from the Company at a price of $0.23 per share. The Company also granted the Underwriters a 45-day option to purchase up to an additional 5,608,470 shares of Common Stock at the same price. The shares were sold in the Offering pursuant to a Registration Statement on Form S-1, as amended (File No. 333-264347) (the “Registration Statement”), a Registration Statement on Form S-1 pursuant to 462(b) of the Securities Act of 1933, as amended (File No. 333-264775), and a related prospectus filed with the Securities and Exchange Commission. The public offering closed on May 10, 2022 and the Company sold 37,389,800 shares of Common Stock for total gross proceeds of $9.3 million. The Company received net proceeds of $8.1 million after deducting underwriters discounts and commissions of $0.7 million and direct offering expenses of $0.5 million. |